Lyxumia
Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin
July 28, 2016Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand
Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
Sanofi escapes most serious censure
December 13, 2013Medical Communications, Sales and Marketing ABPI, Lyxumia, PMCPA, Sanofi, censure
Sanofi has been cleared of the most serious breach of the ABPI Code of Practice – despite appearing to offer …
Sanofi celebrates EU approvals
February 5, 2013Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes
Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …
Positive data for Sanofi’s diabetes drug
June 13, 2012Research and Development, Sales and Marketing Lyxumia, Novo Nordisk, Sanofi, Victoza, diabetes
Sanofi’s new diabetes treatment Lyxumia has significantly reduced glycated hemoglobin (HbA1c) in two late-stage trials, the manufacturer says. Paris-based Sanofi …
